COR

SEC Filing Summary: AmerisourceBergen Corporation (10-Q)

Business Context and Reporting Period

This filing is a Quarterly Report on Form 10-Q for AmerisourceBergen Corporation (now Cencora, Inc.) for the period ended March 31, 2006. The Company is a pharmaceutical services provider operating primarily in the United States through two reportable segments: Pharmaceutical Distribution (including AmerisourceBergen Drug Corporation and Specialty Group) and PharMerica (Long-Term Care and Workers' Compensation). The Company recently completed a two-for-one stock split in December 2005 and adopted SFAS No. 123R for share-based compensation effective October 1, 2005.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Growth: Operating revenue increased 15% year-over-year (Q/Q) and 13% (6-month) driven by the Pharmaceutical Distribution segment. Bulk deliveries increased 24% in the quarter but decreased 4% over six months.
• Profitability: Net income rose 30% in the quarter and 50% over six months compared to the prior year. Diluted EPS increased 36% (Q/Q) and 55% (6-month).
• Segment Performance:
  • Pharmaceutical Distribution: Operating income increased 14% (Q/Q) and 25% (6-month), aided by fee-for-service agreements and generic program growth.
  • PharMerica: Operating income declined 49% (Q/Q) and 38% (6-month) due to reduced compensation for Medicare Part D patients and increased operating expenses.
• Unusual Items: The Company recognized gains of $9.4 million (Q/Q) and $27.4 million (6-month) from antitrust litigation settlements, recorded as a reduction of cost of goods sold. Conversely, facility consolidation and severance costs totaled $3.6 million (Q/Q) and $12.4 million (6-month).
• Acquisitions: The Company acquired Trent Drugs (Canada), Network for Medical Communications & Research (NMCR), Brecon Pharmaceuticals (UK), and Asenda Pharmaceutical Supplies during the period, contributing to goodwill increases.

Guidance, Outlook, and Risks

• Revenue Outlook: Management expects annual operating revenue growth for fiscal 2006 to be between 10% and 12%, an increase from the prior estimate of 7% to 9%.
• PharMerica Margin: Operating income margin for PharMerica is estimated to be between 4% and 5% for fiscal 2006, impacted by Medicare Part D reimbursement changes.
• Cash Flow: Expected cash flow from operations for fiscal 2006 is between $600 million and $700 million.
• Key Risks:
  • Regulatory: Changes in Medicare reimbursement rates (MMA) and potential restrictions on manufacturer rebates for long-term care pharmacies.
  • Operational: Risks associated with the outsourcing of IT activities to IBM and integration of recent international acquisitions.
  • Legal: Ongoing investigation by the New York Attorney General regarding alternate source market purchases.

Investor Verification Checklist

• Medicare Part D Impact: Verify the extent of revenue and margin erosion in the PharMerica segment due to the transition from Medicaid to Medicare Part D reimbursement rates.
• Antitrust Settlements: Confirm the sustainability of earnings given the $27.4 million gain from antitrust settlements included in the six-month results.
• Working Capital Trends: Monitor the increase in Accounts Receivable ($293M increase) and Merchandise Inventories ($305M increase) against cash flow generation.
• Acquisition Integration: Assess the performance and integration costs of recent acquisitions (Trent, NMCR, Brecon, Asenda) against projected synergies.
• Share Repurchases: Note the Company's active buyback program ($132.2M spent in six months) and remaining authorization ($617.8M).